BDX – Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) Monthly Stock Report – November 20, 2025

Company Overview

Becton, Dickinson and Company (BD) is a prominent player in the Medical Instruments and Supplies industry, headquartered in Franklin Lakes, New Jersey. Founded in 1897, BD specializes in developing, manufacturing, and selling a wide array of medical devices and supplies, such as IV catheters, syringes, and diagnostic products. Serving healthcare institutions, life science researchers, and the broader public, the company operates across multiple segments, offering advanced solutions for vascular access, specimen collection, surgical procedures, and laboratory automation.

With a reported total revenue of approximately $21.84 billion, Becton, Dickinson maintains a strong market presence and exemplifies robust financial health. Positioned in the Healthcare sector–an essential industry experiencing continuous growth–BD’s commitment to innovation aids in enhancing healthcare delivery worldwide. This favorable outlook drives a “buy” recommendation for potential investors, with an optimistic target price of $270.

52-Week Price Performance Analysis

The stock of Becton, Dickinson has shown notable volatility over the past year, with the price experiencing a high of $251.99 and a low of $162.29. Currently, the stock trades at $189.625, situated closer to its lower range, indicating considerable upside potential if market conditions strengthen.

Chart Insights

A technical review of BD’s stock price chart reveals a predominantly bearish trend throughout the year. After an initial bullish momentum that peaked in January and February, the stock entered a downward trajectory, ultimately decreasing by 13.41% over the period.

1. Support and Resistance Levels:
2. Support Level: Multiple rebounds around the $180 mark suggest this is a substantive support floor.

3. Resistance Level: A significant resistance barrier exists around $220, where the price has struggled to maintain traction.

4. Trend Analysis:

5. The fifty-day moving average currently rests at $186.7384, with the stock trading slightly above this level.

6. The trendline indicates a downward direction, reinforcing the bearish sentiment until a clear breakout occurs above resistance levels.

7. Momentum Indicators:

8. Recent upward movements toward the $190 mark could signal a potential pause or reversal in the downtrend. However, caution is warranted as the price remains below critical resistance.

In summary, while there are signs of stabilization, BD’s price is currently trending downward, and investors should watch for potential upward movement towards previous highs carefully.

Financial Performance and Metrics

Becton, Dickinson recently reported fiscal fourth-quarter revenue of $5.89 billion, marking an 8.3% year-over-year increase, though it fell slightly short of the consensus estimate of $5.91 billion. The adjusted diluted Earnings Per Share (EPS) rose to $3.96, surpassing expectations by $0.05. Additionally, the company achieved an EBITDA of approximately $5.63 billion, indicating solid operational efficiency.

Key Financial Metrics:

• Total Revenue: $21.84 billion
• EBITDA: $5.63 billion
• Outstanding Shares: 286,627,469
• Short Interest: 1.09% (approximately 3,113,440 shares)
• Current Stock Price: $189.625

The financial analysis indicates a healthy balance sheet and solid profit margins, positioning BD favorably within the medical supply market.

Recent News and Developments

Several recent developments could impact Becton, Dickinson’s stock performance:

1. Leadership Change: CFO Chris DelOrefice will be leaving the company on December 5, 2025. This departure could lead to shifts in company strategy that may affect investor sentiment.

2. Dividend Declaration: BD declared a quarterly dividend of $1.05 per share, a 1.0% increase, continuing its streak of 54 years of annual dividend growth, signifying strong cash flow and commitment to returning value to shareholders.

3. Regulatory Innovations: The company achieved full interoperability of its Alaris infusion pump system across major U.S. electronic health records, initiating implementation at Duncan Regional Hospital. This advancement underscores BD’s commitment to integrating technology into healthcare solutions.

Market Sentiment and Analyst Recommendations

Currently, BD is viewed positively by most analysts, reflected in the consensus recommendation categorized as a “buy.” The mean recommendation score stands at 2.36 based on insights from 12 analysts.

Price Targets:

• Target High Price: $270
• Target Low Price: $183
• Target Mean Price: $201.49
• Target Median Price: $193.50

Stifel has adjusted their price target from $280 to $224, acknowledging potential concerns regarding fiscal estimates for 2026. Despite this adjustment, the overall bullish outlook persists among analysts, backed by the company’s robust fundamentals and growth opportunities in its industry.

Conclusion

Becton, Dickinson and Company remains a significant player in the Medical Instruments and Supplies industry, with promising revenue and profit metrics. The current price presents opportunities for investors to capitalize on potential gains, notably as the stock trades closer to its support levels. However, investors should be vigilant regarding ongoing challenges in the market and the broader economy.

In summary, with its solid financial performance, a commitment to innovation in healthcare, and positive market sentiment, Becton, Dickinson continues to position itself as a valuable investment in the healthcare sector. Investors are encouraged to consider this balance of opportunities and risks as they evaluate potential investment in BD.

Metric	Value
Market Cap	$54.4b
Total Debt	$19.2b
Total Cash	$649.0m
Shares Outstanding	286.6m
Float Shares	285.9m